They are Kenyan, Indian, Palestinian, French, Spanish and, yes, American -- and they have all been affected by terror in their young lives. [Read More]

David Brooks, citing Hillary Clinton's "amazing opportunity", is right: "Dear Hillary ... somehow you're going to have to come up with an updated muscular Clintonism”. [Read More]

"If anyone is claiming that China is enjoying a healthy or robust jobs market, they have no idea what they're talking about". [Read More]

Fifteen major companies have taken "significant action to assist [in] the refugee crisis." Why? [Read More]

As the national politics of income inequality and the minimum wage grind on, two private sector leaders are the latest to take action in these social progress/good business initiatives. [Read More]

It would be facile to attribute the current wave of populism to a single cause. But jobs -- related to standard of living, quality of life -- surely represent a tap root for much of the populism ferment. [Read More]

Sometimes you have to wonder how the U.S. Senate gets anything done. [Read More]

Chief executive officers who work to propel their company's stock price can generate "fleeting benefits and disastrous consequences. A better way to measure whether a C.E.O. has created value at a company is to look at its return on capital over a period of years." [Read More]

It's not easy being a responsible company these days. Especially with new human resources issues now bubbling to a froth in the workplace. [Read More]

Global citizenship reports are delivering "some surprising benefits" ... [Read More]

In-person give-and-take at company shareholder meetings may soon be a thing of the past. But not if some major institutional investors have their way. [Read More]

"Versions of Trump and the kind of politics he represents are popping up everywhere." [Read More]

Pfizer presented blocking of its drugs for lethal injection in a values framework: "Pfizer makes its products to enhance and save the lives of patients we serve. Consistent with these values, Pfizer strongly objects to the use of its products as lethal injections for capital punishment." [Read More]

Mark the date: April 25, 2016. [Read More]

Ending a "bumpy but exhilarating" four years as the reader-advocate at the New York Times, Margaret Sullivan presents a worrisome forecast not only for The Times but, by inference, for the traditional journalism business model as many of us have known it. [Read More]